Amiodarone Therapy Guidelines

Initialization and Monitoring

• After stabilization with an amiodarone loading dose, the patient should be transitioned to an oral maintenance dose of amiodarone (200-400 mg daily) with close monitoring of cardiac rhythm, vital signs, and potential side effects, as recommended by the American Heart Association 1
• Reduce or discontinue other rate-controlling medications if heart rate slows excessively, according to the American Heart Association 1
• Initial administration can be 5-7 mg/kg over 30-60 minutes, followed by 1.2-1.8 g/day continuous IV or divided oral doses until 10 g total 2, 3
• An alternative loading dose of 600-800 mg daily for 7 days (total 4.2-5.6g) is recommended by the American Heart Association 4
• The American College of Cardiology recommends an initial 24-hour administration of 1000 mg amiodarone, consisting of a rapid infusion of 150 mg over 10 minutes, followed by 1 mg/min for 6 hours, and then 0.5 mg/min for the remainder of the period 5

Dosing and Administration

• When converting from intravenous to oral amiodarone, the oral loading dose should be adjusted based on the duration of previous IV therapy, with doses ranging from 400 to 1,600 mg oral amiodarone daily, as follows:

• The maintenance dose is 200-400 mg daily, with lower doses (200 mg daily) potentially being effective with fewer side effects, and patient-specific factors such as age, renal function, and hepatic function should be considered when adjusting the dose 7, 1
• The European Society of Cardiology suggests using the lowest effective dose to minimize side effects, with 200 mg daily often being effective with fewer side effects 8

Monitoring and Side Effects

• Weekly ECG monitoring during initial therapy is recommended to assess PR interval, QRS duration, QT interval, and heart rate, as suggested by the American Heart Association 1
• The American College of Cardiology recommends monitoring thyroid and liver function tests every 6 months, ECG monitoring for QT prolongation and bradycardia, pulmonary function tests if respiratory symptoms develop, and ophthalmologic examination if visual symptoms occur 4
• Common side effects to monitor include bradycardia, hypotension, QT prolongation, gastrointestinal upset, photosensitivity, pulmonary toxicity, and thyroid dysfunction 7
• The American Academy of Family Physicians notes that pulmonary toxicity is the most serious potential adverse effect of amiodarone, requiring prompt assessment of any new respiratory symptoms such as dyspnea or cough 4
• Female gender is associated with a higher incidence of bradycardia, with bradycardia being more common in women than men 2
• Correcting electrolyte abnormalities, especially potassium and magnesium, is crucial in managing bradycardia, as recommended by the European Society of Cardiology 9
• Potassium and magnesium levels should be maintained (>4.0 mEq/L) before and during therapy to prevent electrolyte imbalances 10

Drug Interactions

• Amiodarone inhibits multiple CYP450 enzymes and P-glycoprotein, requiring dose adjustments of concomitant medications, including warfarin, digoxin, and statins, due to significant drug interactions 11, 4
• Clinically significant interactions include:

Indications and Contraindications

• Patients with recurrent episodes of atrial fibrillation, high risk of recurrence, or atrial fibrillation refractory to other treatments should be considered for oral amiodarone therapy 12
• Amiodarone is contraindicated in patients with severe sinus node dysfunction, AV block (in absence of pacemaker), cardiogenic shock, and severe bradycardia, due to the risk of exacerbating these conditions 13, 4
• The European Heart Journal reports that amiodarone is more effective than sotalol or propafenone in preventing recurrence of atrial fibrillation (69% vs 39%) 8

Discontinuation

• The American Academy of Family Physicians recommends discontinuing treatment immediately with tapering if significant adverse effects such as pulmonary toxicity occur 4
• Discontinuation of amiodarone may be considered after an arrhythmia-free period of 6-12 months, or if significant toxicity develops, and the American College of Cardiology recommends that amiodarone should be tapered rather than stopped abruptly due to its long half-life 11, 14
• Consider discontinuation of treatment if the patient has been shock-free for 6-12 months, significant adverse effects develop, or programming adjustments can provide adequate protection 4